Post-earnings recap
Reported
Wed, Apr 30, 2025
EPS actual
$6.63
EPS est.
$6.29
EPS surprise
+5.41%
1-day move
+0.77%
United Therapeutics reported a strong EPS performance, exceeding expectations, which contributed to a modest stock increase of 0.77%. The lack of revenue data and guidance suggests that investors may need to wait for more information in future reports. The positive EPS surprise indicates that the company is managing its costs effectively, but the absence of revenue details leaves some uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $6.63 | N/A | +5.41% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to ongoing strategic initiatives. However, they did not provide specific revenue guidance.
We are pleased with our EPS performance this quarter.
While we did not provide revenue guidance, we remain focused on our strategic initiatives.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—